Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA – Get Free Report) have received an average recommendation of “Moderate Buy” from the five research firms that are currently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $4.50.
A number of research firms recently issued reports on TNYA. Weiss Ratings reissued a “sell (d-)” rating on shares of Tenaya Therapeutics in a research note on Wednesday, January 21st. Chardan Capital reduced their price objective on Tenaya Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, December 12th. HC Wainwright lowered their price objective on shares of Tenaya Therapeutics from $5.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, December 12th. Canaccord Genuity Group cut their price objective on shares of Tenaya Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Finally, Morgan Stanley set a $2.00 price target on Tenaya Therapeutics in a research note on Thursday, January 8th.
Check Out Our Latest Stock Report on Tenaya Therapeutics
Insider Transactions at Tenaya Therapeutics
Institutional Investors Weigh In On Tenaya Therapeutics
Hedge funds have recently bought and sold shares of the company. OMERS ADMINISTRATION Corp acquired a new position in Tenaya Therapeutics during the fourth quarter worth approximately $168,000. Barclays PLC increased its holdings in shares of Tenaya Therapeutics by 18,500,000.0% during the 4th quarter. Barclays PLC now owns 185,001 shares of the company’s stock worth $132,000 after acquiring an additional 185,000 shares during the last quarter. Marshall Wace LLP increased its holdings in shares of Tenaya Therapeutics by 8,034.4% during the 4th quarter. Marshall Wace LLP now owns 1,406,035 shares of the company’s stock worth $998,000 after acquiring an additional 1,388,750 shares during the last quarter. Kalehua Capital Management LLC bought a new stake in Tenaya Therapeutics in the 4th quarter valued at $1,423,000. Finally, Alyeska Investment Group L.P. acquired a new stake in Tenaya Therapeutics during the 4th quarter valued at $2,846,000. 90.54% of the stock is currently owned by institutional investors and hedge funds.
Tenaya Therapeutics Price Performance
Shares of Tenaya Therapeutics stock opened at $0.66 on Tuesday. Tenaya Therapeutics has a 1 year low of $0.36 and a 1 year high of $2.35. The business has a 50-day moving average of $0.78 and a two-hundred day moving average of $1.15. The company has a market capitalization of $108.07 million, a P/E ratio of -0.85 and a beta of 3.18.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.
Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.
Featured Stories
- Five stocks we like better than Tenaya Therapeutics
- Your Bank Account Is No Longer Safe
- Nvidia CEO Issues Bold Tesla Call
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
- This $15 Stock Could Go Down as the #1 Stock of 2026
Receive News & Ratings for Tenaya Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenaya Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
